<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/56443A66-B72D-4164-A2AE-F16898367510"><gtr:id>56443A66-B72D-4164-A2AE-F16898367510</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:address><gtr:line1>PO Box 256</gtr:line1><gtr:postCode>SE-751 05</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4C2CA131-8671-43FC-93C9-205060B9A677"><gtr:id>4C2CA131-8671-43FC-93C9-205060B9A677</gtr:id><gtr:name>Biochemistry</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4E682F0C-74B5-4907-891D-7BAC440B9540"><gtr:id>4E682F0C-74B5-4907-891D-7BAC440B9540</gtr:id><gtr:name>University of Georgia</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D2D9079A-7C22-416E-84A8-4F37FF19A482"><gtr:id>D2D9079A-7C22-416E-84A8-4F37FF19A482</gtr:id><gtr:name>Callaghan Innovation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/08B7FC3F-6505-4352-AE46-A91D9163A583"><gtr:id>08B7FC3F-6505-4352-AE46-A91D9163A583</gtr:id><gtr:name>College of Medicine, Biological Sciences and Psychology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0CF23EC6-EA76-4813-BB6B-803FF1050B4A"><gtr:id>0CF23EC6-EA76-4813-BB6B-803FF1050B4A</gtr:id><gtr:name>Industrial Research Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/308C1B48-278F-44D4-A65F-12A0D8DE1068"><gtr:id>308C1B48-278F-44D4-A65F-12A0D8DE1068</gtr:id><gtr:name>Victoria University of Wellington</gtr:name><gtr:address><gtr:line1>PO Box 600</gtr:line1><gtr:line4>Wellington</gtr:line4><gtr:postCode>6140</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Sch of Biological Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/56443A66-B72D-4164-A2AE-F16898367510"><gtr:id>56443A66-B72D-4164-A2AE-F16898367510</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:address><gtr:line1>PO Box 256</gtr:line1><gtr:postCode>SE-751 05</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4C2CA131-8671-43FC-93C9-205060B9A677"><gtr:id>4C2CA131-8671-43FC-93C9-205060B9A677</gtr:id><gtr:name>Biochemistry</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4E682F0C-74B5-4907-891D-7BAC440B9540"><gtr:id>4E682F0C-74B5-4907-891D-7BAC440B9540</gtr:id><gtr:name>University of Georgia</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D2D9079A-7C22-416E-84A8-4F37FF19A482"><gtr:id>D2D9079A-7C22-416E-84A8-4F37FF19A482</gtr:id><gtr:name>Callaghan Innovation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/08B7FC3F-6505-4352-AE46-A91D9163A583"><gtr:id>08B7FC3F-6505-4352-AE46-A91D9163A583</gtr:id><gtr:name>College of Medicine, Biological Sciences and Psychology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0CF23EC6-EA76-4813-BB6B-803FF1050B4A"><gtr:id>0CF23EC6-EA76-4813-BB6B-803FF1050B4A</gtr:id><gtr:name>Industrial Research Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/308C1B48-278F-44D4-A65F-12A0D8DE1068"><gtr:id>308C1B48-278F-44D4-A65F-12A0D8DE1068</gtr:id><gtr:name>Victoria University of Wellington</gtr:name><gtr:address><gtr:line1>PO Box 600</gtr:line1><gtr:line4>Wellington</gtr:line4><gtr:postCode>6140</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C1333C74-F0AB-4EAE-AD9F-BDCB7B542E13"><gtr:id>C1333C74-F0AB-4EAE-AD9F-BDCB7B542E13</gtr:id><gtr:name>Rensselaer Polytechnic Institute</gtr:name><gtr:address><gtr:line1>Rensselaer Polytechnic Institute</gtr:line1><gtr:line2>110 8th Street</gtr:line2><gtr:line4>Troy</gtr:line4><gtr:line5>New York</gtr:line5><gtr:postCode>NY 12180-3</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3E5E37F6-B311-43AB-9662-07B95D3A22F6"><gtr:id>3E5E37F6-B311-43AB-9662-07B95D3A22F6</gtr:id><gtr:name>University of Georgia (USA)</gtr:name><gtr:address><gtr:line1>University of Georgia</gtr:line1><gtr:line4>Athens</gtr:line4><gtr:line5>Georgia</gtr:line5><gtr:postCode>GA 30602-7</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B2F55FA9-C692-43A1-9E06-19BA7ABEE939"><gtr:id>B2F55FA9-C692-43A1-9E06-19BA7ABEE939</gtr:id><gtr:firstName>Sally Elizabeth</gtr:firstName><gtr:surname>Stringer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9E914223-C27C-4931-937A-02A79D4A0E5D"><gtr:id>9E914223-C27C-4931-937A-02A79D4A0E5D</gtr:id><gtr:firstName>Jamie</gtr:firstName><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9D31B22D-CA64-4E36-B3CB-3DDC0B025901"><gtr:id>9D31B22D-CA64-4E36-B3CB-3DDC0B025901</gtr:id><gtr:firstName>Edwin</gtr:firstName><gtr:otherNames>Alexander</gtr:otherNames><gtr:surname>Yates</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8D381AAA-E001-4B4F-8C29-3C468F3AFC6C"><gtr:id>8D381AAA-E001-4B4F-8C29-3C468F3AFC6C</gtr:id><gtr:firstName>Jerry</gtr:firstName><gtr:surname>Turnbull</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/55BBBE52-3198-4B5A-ADE7-6F7EE6BF38A3"><gtr:id>55BBBE52-3198-4B5A-ADE7-6F7EE6BF38A3</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Fernig</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FD006325%2F1"><gtr:id>DAE9AF37-5FAA-435D-9AAB-D3E15282380A</gtr:id><gtr:title>Chemical intervention in heparan sulphate-dependent growth factor signalling systems using engineered heparin saccharides</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D006325/1</gtr:grantReference><gtr:abstractText>Our labs have expertise in studying the structure and activities of the complex polysaccharide heparan sulphate, which is found on the surface of all cells, and in studying biological processes in cell and developmental biology. These sugars have considerable structural diversity, and bind to many specialised proteins, such as growth factors, responsible for controlling cell behaviour in all tissues. Our labs are interested in finding out more about the molecular basis for their actions and exploiting their exciting natural properties by using them as tools to chemically interfere in biological systems. In this project we are planning to exploit a new approach we have developed for creating libraries of HS sugars with diverse structures, to study the relationships between structure and activity for a number of growth factors. We will examine how differences in structure affect the ability of these sugars to alter growth factor activities in biological assays using test tube, cell and whole animal assays. This will allow us to carry out experiments in a biological system in which targeted intervention of a known pathway and its biological outcome will be conducted. We will collect and compare the data from screening assays to both determine structural specificity amongst diverse growth factors, and identify activating and inhibitory saccharide molecules for application as selective chemical intervention tools in biological systems. We will also use the information to design selected structures for full chemical synthesis and testing, with the aim of providing a supply of defined molecules for future intervention experiments. The ultimate goal will be to establish the application of engineered heparin saccharide as a powerful tool for revealing novel insights into the functional roles of specific HS sequences in regulation of biological systems. These studies will provide new information which will help us to understand how these sugar-protein interactions regulate the functions of cells. They fit into a number of areas within the broad Council remit of increasing understanding of how living organisms function (in this case, molecular interactions relevant to cell signaling and regulation) and providing knowledge which can be used to develop new technologies and products for medicine and industry.</gtr:abstractText><gtr:technicalSummary>Specific sequences in heparan sulfate (HS) determine selective protein binding and regulatory properties and are thus ideally designed as one of Nature's tools for chemical intervention. However, structure-activity studies have been hampered by limited amounts of active sequences available from natural HS. We have developed novel approaches for creating libraries of heparin-based structures 'engineered' to produce a high level of structural diversity, combined with new techniques for their further separation and analysis. This approach allows large numbers of sequences to be searched for activity for the first time, providing an opportunity to develop a generic 'chemical genetics' approach for rapid exploration of structure-activity relationships in biological systems. We will exploit this opportunity by generating a library of highly diverse HS analogue saccharides by chemical modification of poly- and oligo-saccharide heparin templates. Their activity will be screened using established in vitro binding and activity assays for 3 types of growth factors / FGFs, GDNF, and VEGF / and also using relevant ex vivo and in vivo assays in model systems (angiogenesis; kidney development) and whole organisms (C elegans and zebrafish). This will allow us to assess their potential use for targeted intervention of known signaling pathways and examination of the resulting biological outcomes. The data will be collated to determine both the level of structural specificity amongst these different growth factors and to identify activating and inhibitory saccharide molecules for application as selective chemical intervention tools in biological systems. The information gained will be used to prepare saccharide-nanoprobes for testing in biological assays, and also for the design of a limited number of relevant oligosaccharide structures for direct chemical synthesis using newly developed methods (in collaboration with Prof. Geert-Jan Boons, University of Georgia). The latter would provide highly defined chemical tools for intervention in biological systems. The ultimate goal will be to establish the application of engineered heparin saccharides as a powerful tool for revealing novel insights into the functional roles of specific HS sequences in regulation of biological systems.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>546103</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Biochemistry</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Medical Biochemistry</gtr:department><gtr:description>Animal testing of AD secretase inhibitors</gtr:description><gtr:id>81166938-BAD3-4B83-9015-0138BF6B5E28</gtr:id><gtr:impact>IP and patenting + publications</gtr:impact><gtr:partnerContribution>Provision of transgenic mouse models of AD</gtr:partnerContribution><gtr:piContribution>Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>College of Medicine, Biological Sciences and Psychology</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Genetics</gtr:department><gtr:description>Animal testing of AD secretase inhibitors</gtr:description><gtr:id>838114D1-5CDE-441C-8F66-5CE6134595E0</gtr:id><gtr:impact>IP and patenting + publications</gtr:impact><gtr:partnerContribution>Provision of transgenic mouse models of AD</gtr:partnerContribution><gtr:piContribution>Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Uppsala (Uppsala universitet)</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Medical Biochemistry</gtr:department><gtr:description>Animal testing of AD secretase inhibitors</gtr:description><gtr:id>F1BD0DA9-4761-4D34-9C67-1BC1BE37607A</gtr:id><gtr:impact>IP and patenting + publications</gtr:impact><gtr:partnerContribution>Provision of transgenic mouse models of AD</gtr:partnerContribution><gtr:piContribution>Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Callaghan Innovation</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Carbohydrate Chemistry</gtr:department><gtr:description>Synthetic chemistry for HS analogues</gtr:description><gtr:id>ED44820C-0A43-4AE5-B995-F65B513BCBB8</gtr:id><gtr:impact>Publication in JACS and Chem Euro Journal and ongoing collaborations</gtr:impact><gtr:partnerContribution>Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development</gtr:partnerContribution><gtr:piContribution>Design of target molecules for synthesis and provision of bioassays for screening</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Victoria University of Wellington</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Ferrier Research Institute</gtr:department><gtr:description>Development of AD therapeutics</gtr:description><gtr:id>38185237-33DA-4678-A1F4-BFA60A5137EC</gtr:id><gtr:impact>Chem Eur J publication, further manuscripts in preparation, joint funding and IP patent submissions</gtr:impact><gtr:partnerContribution>Developing synthetic chemistry for BACE inhibitors and providing compounds and radiolabelled compounds</gtr:partnerContribution><gtr:piContribution>Providing target structures and bioassays</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Georgia</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Synthetic chemistry for HS analogues</gtr:description><gtr:id>53C28CEC-32D9-4E70-932A-C478F5B62FA1</gtr:id><gtr:impact>Publication in JACS and Chem Euro Journal and ongoing collaborations</gtr:impact><gtr:partnerContribution>Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development</gtr:partnerContribution><gtr:piContribution>Design of target molecules for synthesis and provision of bioassays for screening</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Industrial Research Ltd</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Glycochemistry Division</gtr:department><gtr:description>Synthetic chemistry for HS analogues</gtr:description><gtr:id>74F63AC1-ED07-4D12-BD09-4381F4C618FA</gtr:id><gtr:impact>Publication in JACS and Chem Euro Journal and ongoing collaborations</gtr:impact><gtr:partnerContribution>Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development</gtr:partnerContribution><gtr:piContribution>Design of target molecules for synthesis and provision of bioassays for screening</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Callaghan Innovation</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Carbohydrate Chemistry</gtr:department><gtr:description>Development of AD therapeutics</gtr:description><gtr:id>FC556868-6057-431C-9C55-627AD38D30EA</gtr:id><gtr:impact>Chem Eur J publication, further manuscripts in preparation, joint funding and IP patent submissions</gtr:impact><gtr:partnerContribution>Developing synthetic chemistry for BACE inhibitors and providing compounds and radiolabelled compounds</gtr:partnerContribution><gtr:piContribution>Providing target structures and bioassays</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Callaghan Innovation</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>Synthetic chemistry for heparan sulfate analogues</gtr:description><gtr:id>84A296FD-5B2C-463F-9C6A-73B5A3DDA97C</gtr:id><gtr:piContribution>International collaboration to develop synthetic chemistry for heparin/HS glycans</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Victoria University of Wellington</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Ferrier Research Institute</gtr:department><gtr:description>Synthetic chemistry for HS analogues</gtr:description><gtr:id>1C39F0E9-B44A-4C67-B709-A1E7F02572E3</gtr:id><gtr:impact>Publication in JACS and Chem Euro Journal and ongoing collaborations</gtr:impact><gtr:partnerContribution>Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development</gtr:partnerContribution><gtr:piContribution>Design of target molecules for synthesis and provision of bioassays for screening</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>RCUK/BBSRC event: Lifelong Health: Bioscience of Ageing (at Westminster)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3CDCECAC-82DA-45F9-B43C-EF15FFB282B2</gtr:id><gtr:impact>Poster highlighting discovery of new class of drugs for AD at the RCUK/BBSRC event: 2007 Lifelong Health: Bioscience of Ageing (at Westminster)

Dissemination of information on research success to MPs and policymakers</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Supporting ARUK fund raising publicity with major London donor</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F15F9834-DC65-4417-8A96-81DEB928D8E3</gtr:id><gtr:impact>Supporters engaged directly with researcher undertaking research activity.

As above</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Outreach to Business Community</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>693EF6B4-AFFB-41D8-B9DD-81EBC9ECFF26</gtr:id><gtr:impact>Article in magazine Research Intelligence by UoL Business Gateway,(see website link &amp;quot;Sweet Smell of Success&amp;quot; http://www.liv.ac.uk/researchintelligence/issue30/alzheimers.html)

Dissemination of information to business community</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.liv.ac.uk/researchintelligence/issue30/alzheimers.html</gtr:url><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture to Garston Rotary Club</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AFE44434-CC35-4364-AF65-105075095C92</gtr:id><gtr:impact>Lecture to Garston Rotary Club

Contributing the Public Understanding of Science</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media releases on research findings</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B2EA697D-A4FF-4966-853C-F03E43436987</gtr:id><gtr:impact>University press releases on the novel Alzheimer drug hits we discovered, along with developments in synthetic chemistry of our sugars, and applications in nerve repair and cancer therapeutics

International press coverage, radio interviews (Radio City Liverpool), and TV news (BBC NW Tonight).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture to Liverpool Soroptimists Club</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>982BACA1-9DD5-4B66-9F11-97CB25F79ECF</gtr:id><gtr:impact>Talk sparked many questions and discussion of AD and potential new drugs and diagnostics

Contribution to Public Understanding of Science</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hosting visit to Liverpool University by local ARUK funding supporters</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E8DEB9CD-1EF4-415F-B707-235CC69CB120</gtr:id><gtr:impact>Contact was invaluable in informing supporters directly about research activities supported in Liverpool by their fund raising efforts

Funding supporters were able to gain insights into new potential treatments for AD, and how their funding is used for research.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Exploitation of modified heparins in drug discovery and biotechnology applications</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>F6FCA6C1-2A61-4145-B0B2-6823BE9CEE5B</gtr:id><gtr:impactTypes/><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Platform technology for generating selectively chemivcally modified heparins for drug discovery and biotechnology applications</gtr:description><gtr:id>754D325D-197D-4D74-843A-B8A89AB73EC8</gtr:id><gtr:impact>Licences to University of Liverpool spin out IntelliHep Ltd for exploitation.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US2006240473</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Engineered heparins</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent submitted on novel saccharide inhibitors of beta-secretase as potential therapeutics for Alzheimers disease</gtr:description><gtr:id>809BC152-2914-4854-AC9A-11BB50C6DEEC</gtr:id><gtr:impact>Licenced to IntelliHep Ltd, and ongoing patent costs will be paid by IntelliHep.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2007/138263</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Saccharide inhibitors of beta-secretase</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel class of beta-secretase inhibitors based on natural heparin glycans, with potential as first in class disease-modifying treatment for AD</gtr:description><gtr:id>9D81127F-5FF6-47FC-BF70-F553808AF8AD</gtr:id><gtr:impact>IP licensed to University of Liverpool spinout IntelliHep and currently in further development</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2007138263</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Beta-secretase inhibitors for Alzheimers disease</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel glycodendrimers with potent bioactivities, including inhibition of BACE1.</gtr:description><gtr:id>15E69C0A-22A4-4D24-959B-07FA58EA28B6</gtr:id><gtr:impact>Still in early stage of development</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>PCT/NZ2012/000035</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Novel saccharide dendrimers</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel fully synthetic beta-secretase inhibitors with potential as disease-modifying treatment for AD</gtr:description><gtr:id>D0A0E49C-70B4-4B0E-96A5-BB16837C1EC7</gtr:id><gtr:impact>Further development being undertaken in collaboration with University of Liverpool, and spinout IntelliHep.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2012121617</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Synthetic beta-secretase inhibitors</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>? We have created a novel library of compounds based on a heparin as a chemical scaffold. These &amp;quot;engineered heparins&amp;quot; are a resource that provides a unique toolkit for chemical biology studies on these complex polysaccharides relevant to diverse biological processes. 



? We have demonstrated complex structure-activity relationships of engineered heparin oligosaccharides in in vitro signalling systems including FGFs, VEGF, GDNF and Slit/Robo. These compounds can be used for selective activation or inhibition of these signalling events through altered binding and activation of ligand/receptor interactions. 



? We have tested engineered heparins in ex vivo and in vivo systems and demonstrated that they can be used for selective intervention in signalling processes. One example is selective inhibition or activation of VEGF vs FGF-stimulated angiogenesis in the chick egg CAM assay. Different engineered heparins were found to produce selective pro-angiogenic effects that could have interesting applications in wound healing and tissue engineering. 



? We have conducted an extensive series of experiments testing different engineered heparin oligosaccharides' ability to activate or inhibit different features of kidney development and neurite formation. Some of the oligosaccharides are promising candidates for use in renal tissue engineering, and we are currently exploring their application in this field. 



? We have demonstrated in zebrafish that engineered heparins differentially and specifically regulate angiogenesis in a manner consistent with interference in distinct signalling pathways responsible for formation of branched vessel structures. These compounds will be useful to further dissect the different pathways that contribute to vascular development and may have therapeutic potential. 



? Overall, we have found that engineered heparins represent a privileged region of bioactive chemical space, with great potential for diverse applications in complex biological systems through selective interference in multiple signalling pathways.</gtr:description><gtr:exploitationPathways>Related patent developed from SCIBS compounds: Turnbull JE, Patey SJ &amp;amp; Yates EA. (2006) Oligosaccharide agents for treating Alzheimers disease. WO2007/138263 Patent. This patent has been licenced to a University of Liverpool spin-out company, IntelliHep Ltd (see below) for pre-clinical development.



This SCIBS grant also led to a long term collaboration on development of fully synthetic heparin saccharides, with IRL Ltd, a Crown Research Institute in New Zealand (now Callaghan Innovation).



A spin-out company from the University of Liverpool, IntelliHep Ltd, was developed based on commercial exploitation of chemically modified heparins for biotechnology and drug development applications. Prof Turnbull and Dr Yates were 2 of the Founder scientists. IntelliHep has licenced a patent on compounds for treating Alzheimers disease (based on BBSRC funded project grant and Follow-On Fund grant.



This project also provided a platform for a DTA BBSRC CASE studentship (2007-11)with Chromatide/Spheritech (Runcorn). This project with a local biotech company was underpinned by chemically modified heparins from the SCIBS project. 



Stem Cell Sciences (UK Ltd), 2008-2009: a collaborative project between SCS and IntelliHep Ltd was sub-contracted in to the University (Turnbull and Murray), involving exploitation of chemically modified heparins for human stem cell growth. 



Prof Turnbull and Prof Fernig have also been involved as consultants on a BBSRC-funded SBRI grant to Farfield Sensors Ltd (Crewe) that involved development of smart surfaces for presentation of glycans including modified heparins in optical biosensor instrumentation.</gtr:exploitationPathways><gtr:id>418D37FC-8EEA-45CA-9C8E-5941BB8A707A</gtr:id><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Libraries of selectively chemically modified heparins for applications in heparin-based drug discovery.</gtr:description><gtr:id>31988A54-4E31-4259-8944-7E632BB21FC0</gtr:id><gtr:impact>Exploited for a number of publications and to develop drug leads for AD, malaria, ant-cancer therapeutics and spinal repair therapies.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Engineered heparins</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of technologies for and production of complex libraries of HS saccharides</gtr:description><gtr:id>B68CE422-D541-4C7B-8236-04B5F9EF25D1</gtr:id><gtr:impact>Novel discoveries of structure-activity relationships for complex HS saccharides of relevance to biological and disease processes</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Heparan sulphate saccharide libraries</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>IntelliHep Ltd</gtr:companyName><gtr:description>Spin-out company from University of Liverpool aiming to exploit engineered heparins in drug discovery and biotechnology applications. Company has a number of collaborative projects with external partners, and is also developing an internal pipeline of projects. Company is pre-investment and established a lab in 2010 and seeking further grant and investment income.; http://www.intellihep.com/</gtr:description><gtr:id>6B4A3342-C1C7-47EA-AF29-484803D0C9D3</gtr:id><gtr:impact>Early stage development of hit compounds as beta-secretase inhibitors for treating the underlying cause of Alzheimers disease. Option to licence IP from Liverpool University on an anticancer metastatic drug. Employment of research staff and regular funded projects sub-contracted into University labs. Collaborating with China partners on commercial applications of heparin by-products.</gtr:impact><gtr:url>http://www.intellihep.com/</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27673685-3126-4722-87AC-3B90DF9B90E6"><gtr:id>27673685-3126-4722-87AC-3B90DF9B90E6</gtr:id><gtr:title>Heparan sulphate glycodendrimers with potent bioactivities: tools for chemical biology and therapeutic development.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7fb614b3ab31aae44505c52c29cd6243"><gtr:id>7fb614b3ab31aae44505c52c29cd6243</gtr:id><gtr:otherNames>Zubkova, O</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37C2C32F-358F-41E8-B9DA-22DB9F942B16"><gtr:id>37C2C32F-358F-41E8-B9DA-22DB9F942B16</gtr:id><gtr:title>Generating heparan sulfate saccharide libraries for glycomics applications.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e22a32a9ea715e6a3ab22dbfd6684919"><gtr:id>e22a32a9ea715e6a3ab22dbfd6684919</gtr:id><gtr:otherNames>Powell AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5E4C8E5-971F-4F92-9FE0-28AA29E1ADCE"><gtr:id>C5E4C8E5-971F-4F92-9FE0-28AA29E1ADCE</gtr:id><gtr:title>Chemistry. Getting the farm out of pharma for heparin production.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57b32cbe5f2a1d3281657bf15f25cbfb"><gtr:id>57b32cbe5f2a1d3281657bf15f25cbfb</gtr:id><gtr:otherNames>Turnbull JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1235CA9B-0A09-4AC5-925E-0DE16E18CC25"><gtr:id>1235CA9B-0A09-4AC5-925E-0DE16E18CC25</gtr:id><gtr:title>Structure and epitope distribution of heparan sulfate is disrupted in experimental lung hypoplasia: a glycobiological epigenetic cause for malformation?</gtr:title><gtr:parentPublicationTitle>BMC developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d786766af912a1cf264e031e1e6b8239"><gtr:id>d786766af912a1cf264e031e1e6b8239</gtr:id><gtr:otherNames>Thompson SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-213X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9AD4151A-30DF-4C1C-960E-C9D867E33F0B"><gtr:id>9AD4151A-30DF-4C1C-960E-C9D867E33F0B</gtr:id><gtr:title>Rapid purification and high sensitivity analysis of heparan sulfate from cells and tissues: toward glycomics profiling.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b4f51e190a92a1cba9a8042b8d614d69"><gtr:id>b4f51e190a92a1cba9a8042b8d614d69</gtr:id><gtr:otherNames>Guimond SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C409CC17-46A9-4C0E-AA1B-E6F803458B3E"><gtr:id>C409CC17-46A9-4C0E-AA1B-E6F803458B3E</gtr:id><gtr:title>Heparan sulfate glycomics: towards systems biology strategies.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57b32cbe5f2a1d3281657bf15f25cbfb"><gtr:id>57b32cbe5f2a1d3281657bf15f25cbfb</gtr:id><gtr:otherNames>Turnbull JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87CA3A87-F6D5-48C7-95E2-1556A54080DF"><gtr:id>87CA3A87-F6D5-48C7-95E2-1556A54080DF</gtr:id><gtr:title>Novel 'phage display antibodies identify distinct heparan sulfate domains in developing mammalian lung.</gtr:title><gtr:parentPublicationTitle>Pediatric surgery international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d786766af912a1cf264e031e1e6b8239"><gtr:id>d786766af912a1cf264e031e1e6b8239</gtr:id><gtr:otherNames>Thompson SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0179-0358</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF496AED-D4D9-4D13-96BE-8AA4DFF652C1"><gtr:id>EF496AED-D4D9-4D13-96BE-8AA4DFF652C1</gtr:id><gtr:title>Influence of substitution pattern and cation binding on conformation and activity in heparin derivatives.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/558a73c42b43e2a74e4727d5253ac596"><gtr:id>558a73c42b43e2a74e4727d5253ac596</gtr:id><gtr:otherNames>Rudd TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58A3BEAC-CBA0-4806-A480-A140E75757AC"><gtr:id>58A3BEAC-CBA0-4806-A480-A140E75757AC</gtr:id><gtr:title>Disaccharide compositional analysis of heparan sulfate and heparin polysaccharides using UV or high-sensitivity fluorescence (BODIPY) detection.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/525f0aa9b75a329ba02b752c076c7854"><gtr:id>525f0aa9b75a329ba02b752c076c7854</gtr:id><gtr:otherNames>Skidmore MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/80BF38CD-26F7-4253-A295-0195A9860107"><gtr:id>80BF38CD-26F7-4253-A295-0195A9860107</gtr:id><gtr:title>High sensitivity separation and detection of heparan sulfate disaccharides.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/525f0aa9b75a329ba02b752c076c7854"><gtr:id>525f0aa9b75a329ba02b752c076c7854</gtr:id><gtr:otherNames>Skidmore MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A8692F08-1959-41F0-B14D-628765508D86"><gtr:id>A8692F08-1959-41F0-B14D-628765508D86</gtr:id><gtr:title>Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.</gtr:title><gtr:parentPublicationTitle>Neuro-degenerative diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c3b7fef8dafe1d37d73127af64c17a7"><gtr:id>5c3b7fef8dafe1d37d73127af64c17a7</gtr:id><gtr:otherNames>Patey SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1660-2854</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD2FEB00-9504-4E5A-A7D9-DDCAFC2F322B"><gtr:id>AD2FEB00-9504-4E5A-A7D9-DDCAFC2F322B</gtr:id><gtr:title>Synthesis of a targeted library of heparan sulfate hexa- to dodecasaccharides as inhibitors of ?-secretase: potential therapeutics for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50dd39d48ac6d8d38b428a78a915072c"><gtr:id>50dd39d48ac6d8d38b428a78a915072c</gtr:id><gtr:otherNames>Schw?rer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8949A1E6-CC82-4C77-B1F8-A497A9A84DF8"><gtr:id>8949A1E6-CC82-4C77-B1F8-A497A9A84DF8</gtr:id><gtr:title>Array-based functional screening of heparin glycans.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/01dd6d48ee833a5f06d83163d6525b21"><gtr:id>01dd6d48ee833a5f06d83163d6525b21</gtr:id><gtr:otherNames>Puvirajesinghe TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/432F55A6-2F84-43A9-8D1E-38FD425F0987"><gtr:id>432F55A6-2F84-43A9-8D1E-38FD425F0987</gtr:id><gtr:title>Towards GAG glycomics: analysis of highly sulfated heparins by MALDI-TOF mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0db40194255c6ace68aa3e221566dc76"><gtr:id>0db40194255c6ace68aa3e221566dc76</gtr:id><gtr:otherNames>Tissot B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/133E0C15-1551-423E-82D9-F6A8EA4734B2"><gtr:id>133E0C15-1551-423E-82D9-F6A8EA4734B2</gtr:id><gtr:title>Identification of Orally Available Synthetic Heparinoids with Potent BACE1 Inhibitory Properties</gtr:title><gtr:parentPublicationTitle>Nature Biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/02ff6f916a640dd4c53546bda256c381"><gtr:id>02ff6f916a640dd4c53546bda256c381</gtr:id><gtr:otherNames>Turnbull, JE</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD830FF1-0966-4DD5-846C-2D7CA100712F"><gtr:id>DD830FF1-0966-4DD5-846C-2D7CA100712F</gtr:id><gtr:title>Synthesis of a targeted library of heparan sulfate hexa- to dodecasaccharides as inhibitors of ?-secretase: potential therapeutics for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50dd39d48ac6d8d38b428a78a915072c"><gtr:id>50dd39d48ac6d8d38b428a78a915072c</gtr:id><gtr:otherNames>Schw?rer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/302F727E-3B7D-4FAE-B5C6-0FA9AD8BFE48"><gtr:id>302F727E-3B7D-4FAE-B5C6-0FA9AD8BFE48</gtr:id><gtr:title>Fabrication of carbohydrate microarrays on gold surfaces: direct attachment of nonderivatized oligosaccharides to hydrazide-modified self-assembled monolayers.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6872f6960c5afb96eb5c4b6d2c3d2354"><gtr:id>6872f6960c5afb96eb5c4b6d2c3d2354</gtr:id><gtr:otherNames>Zhi ZL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/439E8E71-7561-4CF3-93E4-85911C65EA4A"><gtr:id>439E8E71-7561-4CF3-93E4-85911C65EA4A</gtr:id><gtr:title>Novel ex vivo transgenic mouse brain tissue assay for screening BACE1 inhibitors</gtr:title><gtr:parentPublicationTitle>Nature Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/092804ddacbc4778ce8b19029aa8303d"><gtr:id>092804ddacbc4778ce8b19029aa8303d</gtr:id><gtr:otherNames>Guimond, SE</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9EC81030-AEE5-4939-BFAC-9F8BB0141F53"><gtr:id>9EC81030-AEE5-4939-BFAC-9F8BB0141F53</gtr:id><gtr:title>Software tool for the structural determination of glycosaminoglycans by mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0db40194255c6ace68aa3e221566dc76"><gtr:id>0db40194255c6ace68aa3e221566dc76</gtr:id><gtr:otherNames>Tissot B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A61BB16-7C2D-4802-BAD5-C09753C9BACD"><gtr:id>9A61BB16-7C2D-4802-BAD5-C09753C9BACD</gtr:id><gtr:title>Nanoscale self-assembled multivalent (SAMul) heparin binders in highly competitive, biologically relevant, aqueous media</gtr:title><gtr:parentPublicationTitle>Chemical Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed920437f418d218567bb635f85f09b2"><gtr:id>ed920437f418d218567bb635f85f09b2</gtr:id><gtr:otherNames>Bromfield S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF8193C1-2154-4B76-A485-ABC4F52085EE"><gtr:id>DF8193C1-2154-4B76-A485-ABC4F52085EE</gtr:id><gtr:title>A versatile gold surface approach for fabrication and interrogation of glycoarrays.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6872f6960c5afb96eb5c4b6d2c3d2354"><gtr:id>6872f6960c5afb96eb5c4b6d2c3d2354</gtr:id><gtr:otherNames>Zhi ZL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38A786DA-B4F7-4B94-94A6-58BFC1BCB605"><gtr:id>38A786DA-B4F7-4B94-94A6-58BFC1BCB605</gtr:id><gtr:title>Synthetic sugars enhance the functional glycomics toolkit.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57b32cbe5f2a1d3281657bf15f25cbfb"><gtr:id>57b32cbe5f2a1d3281657bf15f25cbfb</gtr:id><gtr:otherNames>Turnbull JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/984C3970-6DEC-4360-A8CA-A0647105A8BE"><gtr:id>984C3970-6DEC-4360-A8CA-A0647105A8BE</gtr:id><gtr:title>Glycomics profiling of heparan sulfate structure and activity.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57b32cbe5f2a1d3281657bf15f25cbfb"><gtr:id>57b32cbe5f2a1d3281657bf15f25cbfb</gtr:id><gtr:otherNames>Turnbull JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D006325/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>